Wilson Sonsini Goodrich & Rosati represented Insilico in the transaction. Stemline Therapeutics, Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Exelixis, Inc. and Insilico Medicine announced that they have entered into an exclusive license agreement granting Exelixis...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the transaction. Insilico Medicine, a clinical-stage artificial intelligence-driven drug discovery company, announced a multi-year, multi-target strategic research...
You must be a Standard 1 Year member to access this content.
Davis Polk advised InSilico Medicine in the transaction. InSilico Medicine completed its $35 million Series D2 financing, bringing the total Series D financing to $95 million....
You must be a Standard 1 Year member to access this content.
Davis Polk advised InSilico Medicine in the transaction. InSilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, closed its $60 million Series D financing...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised EQRx in the deal while Wilson Sonsini Goodrich & Rosati represented InSilico. EQRx annlounced a strategic collaboration with Insilico Medicine to jointly...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Insilico Medicine on the deal. Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a leading innovation-driven international healthcare group in China, and...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised InSilico Medicine on the deal. Ashurst represented Mirae Asset Capital. Hong Kong-based InSilico Medicine, a global leader in end-to-end artificial...
You must be a Standard 1 Year member to access this content.
